Pfizer’s cancer drug Adcetris extended survival in patients with a common form of lymphoma in a late-stage trial, the company announced Tuesday, supporting Pfizer’s efforts to expand into ...

Adcetris (brentuximab vedotin) is prescribed for certain types of lymphoma. It comes as a powder that’s made into a solution for infusion into a vein. You usually receive it once every 2 or 3 weeks.

March 12 (Reuters) - Pfizer said on Tuesday its drug, Adcetris, extended survival in patients with the most common type of lymphoma in a late-stage study, bolstering efforts to expand the use of ...

This marks the eighth FDA-approved indication for ADCETRIS, solidifying its role in the treatment of lymphomas. According to InvestingPro analysis, Pfizer's stock is currently trading near its 52 ...

ECHELON-3 trial of ADCETRIS in combination with lenalidomide and rituximab showed significant improvement in primary endpoint of overall survival and in secondary endpoints of progression free ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green light to treat large B-cell lymphoma (LBCL). The CD30-directed antibody ...

Seagen Inc. announced updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027) evaluating the antibody-drug conjugate Adcetris (brentuximab vedotin) in combination ...

The Food and Drug Administration (FDA) has approved Adcetris ® (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical ...

FDA approved Adcetris, Revlimid, and Rituxan for relapsed/refractory LBCL patients ineligible for auto-HSCT or CAR-T therapy, based on ECHELON-3 trial results. The combination therapy showed ...

Adcetris (brentuximab vedotin) is a brand-name drug that’s prescribed for certain lymphomas in adults and some children. It’s typically given via intravenous infusion every 2 or 3 weeks by a ...